Filing Flows › Comparisons › ZYME vs ABCL
Zymeworks vs AbCellera Biologics: ZYME and ABCL compared
Zymeworks is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $4.0M for AbCellera Biologics (Q2 2026). AbCellera Biologics is growing faster (-76% against -91% a year earlier).
Where the money goes: ZYME and ABCL
Zymeworks (ZYME) · Q2 2026
Zymeworks, Q2 2026: revenue $4.6M (-91% year over year), operating margin -919.0%, net loss $45.0M, operating cash flow −$31.9M. The chart follows the revenue to costs, profit and cash.
AbCellera Biologics (ABCL) · Q2 2026
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
| Zymeworks (ZYME) | AbCellera Biologics (ABCL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $4.6M | $4.0M |
| Revenue growth, Y/Y | -91% | -76% |
| Operating margin | -919.0% | n/m |
| Net earnings | −$45.0M | −$55.4M |
| Net margin | -980.8% | — |
| Operating cash flow | −$31.9M | $25.9M |
| Free cash flow | — | $23.8M |
| Market value | $1.9B | $3.8B |
| Analysts’ mean target | $41.50 | $17.17 |
Where the revenue comes from
AbCellera Biologics
- Research fees: $3.9M (96%)
- Licensing and royalty revenue: $149K (4%)
Questions
Which is bigger, Zymeworks or AbCellera Biologics?
Zymeworks is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $4.0M for AbCellera Biologics (Q2 2026).
Is Zymeworks or AbCellera Biologics growing faster?
AbCellera Biologics is growing faster (-76% against -91% a year earlier).
More: Zymeworks earnings · how Zymeworks makes money · AbCellera Biologics earnings · how AbCellera Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.